RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE Open IND for the prophylactic evaluation of PHVS416 Strong pre-IPO cash and
RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE Open IND for the prophylactic evaluation of PHVS416 Strong pre-IPO cash and